Saturday, September 12th, 2020

Live Webcast: 7:45 AM - 6:00 PM EDT

Following an increase in the number of patients presenting with hyperlipidemia, obesity, diabetes, and hypertension, there has been a parallel rise in recent years in the incidence and prevalence of cardiovascular complications. Cardiometabolic risk incorporates a collection of risk factors that predispose individuals to cardiovascular disease (CVD). The 4th Annual New York Cardio-Endo-Renal Collaborative (NY CERC) will focus on strategic and novel approaches to management of integrated cardiometabolic diseases and deliver state-of-the-art clinical updates and strategies aimed at the intersection of metabolic disease and CVD prevention and management.

This activity is supported by educational grants from Akebia Therapeutics Inc., AstraZeneca, and Pfizer-Merck Alliance.

Physicians’ Education Resource^®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource^®, LLC, designates this live activity for a maximum of 8.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource^®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 8.25 Contact Hours.

This educational activity is directed toward cardiologists, endocrinologists, specialty nurse practitioners, specialty physician assistants, certified diabetes educators, other specialty allied health professionals, nephrologists, and other health care professionals.

• Gain insights into the importance of screening and early detection of cardiometabolic risk factors for early and efficacious management to prevent irreversible cardiovascular damage
• Improve competence regarding the integration of novel and newly approved therapies in the management of cardiovascular, renal, and metabolic diseases
• Increase awareness of strategies for overcoming barriers to multidisciplinary care of patients with cardiac, endocrine, and renal disease
• Determine optimal treatment algorithms for specific patient groups
• Hear how leading experts and your peers are managing treatment for their patients with cardiac, renal, and metabolic diseases

• Primary and secondary prevention of cardiovascular disease
• Beyond statins: other low-density lipoprotein cholesterol–lowering treatments
• Guide to anticoagulant therapy
• Advances in heart failure management
• Clinical recognition and management of amyloidosis
• Updates to standards of care in diabetes
• Prevention and management of hypoglycemia
• Management of acute and chronic hyperkalemia
• Cardiometabolic risk reduction in comorbid conditions
• Current and future role of lipoprotein(a)

Upon successful completion of this educational activity, you should be better prepared to:

• Discuss clinical strategies for evaluation and diagnosis of patients presenting with cardiac, endocrine, and renal disease
• Discern the potential clinical impact of recent clinical trial data on management of cardiac, endocrine, and renal disease
• Identify current strategies and recent advances in the prevention of cardiometabolic disorders
• Employ strategies for patient counseling to improve education, preventive practices, adherence, and self-management